'%2F%3E%3Cpath%20d%3D'M6.5%2025%2016%207%2025.5%2025'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.8'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'16'%20cy%3D'19'%20r%3D'3.2'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
KIMIA BIOSCIENCES LIMITED
KIMIABL (BSE 530313) · ISIN INE285U01025 · Pharmaceuticals · Est. 1993 · listed 1995 · website
Not on any surveillance list
Quarterly results
No quarterly results stored for this company yet.
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹17.72 cr | ₹34.63 cr | ₹103.2 cr |
| 30 Sep 2025 standalone | ₹11.59 cr | ₹35.71 cr | ₹101.49 cr |
| 31 Mar 2025 standalone | ₹9.97 cr | ₹32.57 cr | ₹111.21 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 74.94% | — | 0.38% | 25.06% |
Latest filings
- Declaration of Results of Remote E voting and Evoting at AGM held on 28.09.2026 along with Scruitiniser Report provided by Maya Sharma and Associates Company secretaries under regulation .... 29 September 2026 · BSE
- Submission of proceedings of the 33rd Annual General Meeting pursuant to regulations 30 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 28 September 2026 · BSE
- Annual Report FY2025-26 (New) 4 September 2026 · BSE
- Intimation of 33rd Annual General Meeting of the Company proposed to be held on September 28, 2026 at 03:00 P.M. through Video Conferencing/ Other Audio Visual Means. 4 September 2026 · BSE
- Approval of unaudited financial result (Standalone) for quarter ended june 30, 2026. 10 August 2026 · BSE
Other companies in Pharmaceuticals
- Sun Pharmaceutical Industries Limited
- Lupin Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Mankind Pharma Limited
- Aurobindo Pharma Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.